	US 12,076,326 B2
	Crystalline forms of a ryanodine receptor modulator and uses thereof
Pascal Taulelle, Le Havre (FR); and Sandro Belvedere, New York, NY (US)
Assigned to ARMGO Pharma, Inc., Ardsley, NY (US)
Filed by ARMGO Pharma, Inc., Ardsley, NY (US)
Filed on Oct. 17, 2022, as Appl. No. 17/967,301.
Application 17/967,301 is a continuation of application No. 17/571,038, filed on Jan. 7, 2022, granted, now 11,504,383.
Claims priority of provisional application 63/135,083, filed on Jan. 8, 2021.
Prior Publication US 2023/0075141 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 281/10 (2006.01); A61K 31/554 (2006.01); A61P 9/00 (2006.01); A61P 21/00 (2006.01)

CPC A61K 31/554 (2013.01)

25 Claims

1. A crystalline form of 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, wherein if a melting point of the crystalline form is obtained by:

(a) equilibrating a sample of said crystalline form at a temperature of about 20° C. in a temperature-controlled chamber; and

(b) increasing the temperature of the temperature-controlled chamber at about 10° C./minute to 250° C. using a differential scanning calorimetry instrument,

then a melting point of 208-210° C.(T_onset) is obtained.